药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Arformoterol
Aluminium phosphate
Aluminium phosphate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Calcium silicate
Calcium silicate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Aloglutamol
Aloglutamol can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Aluminium glycinate
Aluminium glycinate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Almasilate
Almasilate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium peroxide
Magnesium peroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Hydrotalcite
Hydrotalcite can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Aluminium acetoacetate
Aluminium acetoacetate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium silicate
Magnesium silicate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Bismuth subnitrate
Bismuth subnitrate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium carbonate
Magnesium carbonate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium trisilicate
Magnesium trisilicate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium hydroxide
Magnesium hydroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magaldrate
Magaldrate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Calcium carbonate
Calcium carbonate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Aluminum hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Magnesium oxide
Magnesium oxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Aluminium
Aluminium can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Arformoterol
Revefenacin
Rilpivirine may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Arformoterol
Bempedoic acid
The excretion of Bempedoic acid can be decreased when combined with Rilpivirine.